Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.87 USD
Change Today -0.15 / -1.00%
Volume 17.6K
ALPMY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc-unsp adr (ALPMY) Key Developments

Astellas Pharma, Inc., Q1 2016 Earnings Call, Jul 31, 2015

Astellas Pharma, Inc., Q1 2016 Earnings Call, Jul 31, 2015

Astellas Pharma, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Earnings Guidance on Core and Full Basis for the Fiscal Year 2015

Astellas Pharma, Inc. announced consolidated earnings results for the first quarter ended June 30, 2015. For the period, the company reported sales of JPY 343,659 million against JPY 295,157 million a year ago. Operating profit was JPY 61,911 million against JPY 50,565 million a year ago. Profit before tax was JPY 67,664 million against JPY 50,278 million a year ago. Profit attributable to owners of the parent was JPY 44,622 million against JPY 35,861 million a year ago. Earnings per diluted share were JPY 20.35 against JPY 16.13 a year ago. Net cash flows from operating activities was JPY 29,642 million against JPY 60,653 million a year ago. Purchases of property, plant and equipment was JPY 9,236 million against JPY 5,348 million a year ago. Purchase of intangible assets was JPY 5,924 million against JPY 11,519 million a year ago. Core operating profit was JPY 67,820 million against JPY 65,976 million a year ago. Core profit for the period was JPY 46,409 million against JPY 45,031 million a year ago. For the fiscal year 2015, on core basis, sales are expected to be JPY 1,362,000 million, Core operating profit is expected to be JPY 238,000 million, Core profit for the year is expected to be JPY 170,000 million and basic core earnings per share is expected to be JPY 78.08. For the fiscal year 2015, on full basis, sales are expected to be JPY 1,362,000 million, operating profit is expected to be JPY 238,000 million, profit before tax is expected to be JPY 239,000 million, profit for the year is expected to be JPY 170,000 million and basic earnings per share is expected to be JPY 78.08.

Astellas Pharma, Inc. Provides Dividend Guidance for the Full Year of 2015

Astellas Pharma, Inc. provided dividend guidance for the full year of 2015. For the year, the company expects to pay JPY 32 per share against JPY 30 per share paid a year ago.

Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections

Astellas announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections. Results from the study demonstrated that the trial did not meet its primary endpoint of non-inferiority in overall treatment response in isavuconazole-treated patients at the end of IV therapy compared to caspofungin. The key secondary endpoint of IV isavuconazole followed by either IV or oral isavuconazole versus IV caspofungin followed by either IV caspofungin or oral voriconazole was comparable between groups. The overall safety profile for isavuconazole was similar to caspofungin and consistent with safety data seen in the previously reported Phase 3 studies with isavuconazole.

Astellas Pharma, Inc. to Report Q1, 2016 Results on Jul 31, 2015

Astellas Pharma, Inc. announced that they will report Q1, 2016 results on Jul 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $14.87 USD -0.15

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $142.83 USD -0.12
Boston Scientific Corp $17.07 USD +0.13
CSL Ltd A$92.62 AUD -0.13
Mylan NV $50.37 USD -1.12
Solvay SA €106.35 EUR +0.45
View Industry Companies
 

Industry Analysis

ALPMY

Industry Average

Valuation ALPMY Industry Range
Price/Earnings 27.7x
Price/Sales 3.1x
Price/Book 3.0x
Price/Cash Flow 21.8x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.